- Home
- GRX vs YARW Comparison
GRX vs YARW Comparison
Compare GRX & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRX | YARW |
|---|---|---|
| Founded | N/A | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.5M | 154.5M |
| IPO Year | 2007 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GRX | YARW |
|---|---|---|
| Price | $9.99 | $19.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $57.00 |
| AVG Volume (30 Days) | 12.2K | ★ 93.4K |
| Earning Date | 01-01-0001 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.80 | $18.05 |
| 52 Week High | $10.20 | $44.28 |
Technical Indicators
Market Signals| Indicator | GRX | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 60.44 | 39.92 |
| Support Level | $9.59 | $18.05 |
| Resistance Level | $10.05 | $43.81 |
| Average True Range (ATR) | 0.11 | 1.54 |
| MACD | 0.04 | 0.47 |
| Stochastic Oscillator | 74.77 | 61.07 |
Price Performance
Historical ComparisonAbout GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.